| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b13bb9fd43500aa940816f41eca537c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y204-01212 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y204-01212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84fe7fa6532c628cbb2a38761549b3fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dea145462c6490a8e5d427afd8b0677
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdcdc2188ae881d18740d8edfbe32d30 |
| publicationDate |
2022-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2771490-C2 |
| titleOfInvention |
Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, suitable in treatment of osteoarthritis and similar joint diseases in mammals |
| abstract |
FIELD: medicine.SUBSTANCE: recombinant adeno associated virus (hereinafter – rAAV) is proposed for the treatment of osteoarthritis (hereinafter – OA), containing rAAV vector with a nucleic acid sequence encoding polypeptide of canine hyaluronsintase 2 (hereinafter – HAS2) functionally connected to promotor. A pharmaceutical composition is proposed, containing the specified rAAV, as well as its use for the treatment of OA. A method is proposed for the treatment of a mammal subject suffering from OA, including intra-articular injection of therapeutically effective amount of rAAV.EFFECT: proposed group of inventions provides for the achievement of polypeptide HAS2 expression in joint cells in vivo for the treatment of OA.18 cl, 19 dwg, 3 ex |
| priorityDate |
2016-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |